COST-EFFECTIVENESS OF  LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW

Mustafa Zeybek; Vahit Yiğit

Makale detayları

COST-EFFECTIVENESS OF LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW

Yazarlar:

Mustafa Zeybek | Vahit Yiğit

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Sağlık Yönetimi

Dergi:

SDÜ Sağlık Yönetimi Dergisi Vol.6 Issue 1, pp.13-27

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001320991

pISSN:

2757-5888

Anahtar kelimeler:

Özet:

 End-stage heart failure is a syndrome that occurs when the heart is unable to fully perform its function. Due to the inability to pump enough blood to the body, various disorders accompany end-stage heart failure. The gold treatment for end-stage heart failure is heart transplantation, but LVAD treatment is applied due to the lack of sufficient donors. The aim of this study is to perform a systematic review of studies that reveal the economic evaluation of LVAD treatment. Four databases PubMed, Web of Science, Science Direct, EBSCHO and Ulakbim were searched for the period 2000-2023. The search yielded 165 articles and 20 articles were included in the study based on various inclusion and exclusion criteria. The quality of the included articles was evaluated by the researchers using the CHEERS score. It was observed that most of the articles were conducted between 2012-2017 35, were conducted from a reimbursement perspective 80, and generally took a lifetime time frame 70. The studies mostly applied a 3 discount rate 40 and generally used the Markov model 75. In the systematic review, LVAD was found to be above the cost-effectiveness thresholds of the countries, both as a target treatment and as a bridge treatment, with the exception of the Japanese study. For LVAD to be cost-effective, it is recommended to reduce the acquisition cost.

 End-stage heart failure is a syndrome that occurs when the heart is unable to fully perform its function. Due to the inability to pump enough blood to the body, various disorders accompany end-stage heart failure. The gold treatment for end-stage heart failure is heart transplantation, but LVAD treatment is applied due to the lack of sufficient donors. The aim of this study is to perform a systematic review of studies that reveal the economic evaluation of LVAD treatment. Four databases PubMed, Web of Science, Science Direct, EBSCHO and Ulakbim were searched for the period 2000-2023. The search yielded 165 articles and 20 articles were included in the study based on various inclusion and exclusion criteria. The quality of the included articles was evaluated by the researchers using the CHEERS score. It was observed that most of the articles were conducted between 2012-2017 35, were conducted from a reimbursement perspective 80, and generally took a lifetime time frame 70. The studies mostly applied a 3 discount rate 40 and generally used the Markov model 75. In the systematic review, LVAD was found to be above the cost-effectiveness thresholds of the countries, both as a target treatment and as a bridge treatment, with the exception of the Japanese study. For LVAD to be cost-effective, it is recommended to reduce the acquisition cost.

 End-stage heart failure is a syndrome that occurs when the heart is unable to fully perform its function. Due to the inability to pump enough blood to the body, various disorders accompany end-stage heart failure. The gold treatment for end-stage heart failure is heart transplantation, but LVAD treatment is applied due to the lack of sufficient donors. The aim of this study is to perform a systematic review of studies that reveal the economic evaluation of LVAD treatment. Four databases PubMed, Web of Science, Science Direct, EBSCHO and Ulakbim were searched for the period 2000-2023. The search yielded 165 articles and 20 articles were included in the study based on various inclusion and exclusion criteria. The quality of the included articles was evaluated by the researchers using the CHEERS score. It was observed that most of the articles were conducted between 2012-2017 35, were conducted from a reimbursement perspective 80, and generally took a lifetime time frame 70. The studies mostly applied a 3 discount rate 40 and generally used the Markov model 75. In the systematic review, LVAD was found to be above the cost-effectiveness thresholds of the countries, both as a target treatment and as a bridge treatment, with the exception of the Japanese study. For LVAD to be cost-effective, it is recommended to reduce the acquisition cost.

 Son dönem kalp yetmezliği, kalbin görevini tam olarak yerine getirememesi sonucu ortaya çıkan bir sendromdur. Vücuda yeterli kanın pompalanamaması nedeniyle çeşitli rahatsızlıklarda son dönem kalp yetmezliğine eşlik etmektedir. Son dönem kalp yetmezliğinin altın tedavisi kalp naklidir ancak yeterli donör bulunamaması nedeniyle LVAD tedavisi uygulanmaktadır. Bu çalışmanın amacı, LVAD tedavisinin ekonomik değerlendirmesini ortaya koyan araştırmaların sistematik taramasını gerçekleştirmektir. Sistematik tarama kapsamında 2000-2023 yılları arasını içerecek şekilde dört veri tabanı PubMed, Web of Science, Science Direct, EBSCHO ve Ulakbim taranmıştır. Tarama kapsamında 165 makale bulunmuş ve çeşitli dâhil etme ve dışlama kriterleri kapsamında 20 makale çalışmaya alınmıştır. Dâhil edilen makalelerin kaliteleri CHEERS puanı ile araştırmacılar tarafından değerlendirilmiştir. Araştırmaların en çok 2012-2017 yılları arasında yapıldığı 35, geri ödeyici perspektiften gerçekleştirildiği 80 ve genellikle ömür boyu zaman dilimi 70 alındığı görülmüştür. Çalışmalarda çoğunlukla 3 indirim oranı uygulanmış 40 ve genellikle markov modeli 75 kullanılmıştır. Sistematik tarama sonucunda Japonyada yapılan çalışma haricinde LVAD hem hedef tedavi olarak hem de köprü tedavi olarak, ülkelerin maliyet etkililik eşiklerinin üzerinde bulunmuştur. LVADın maliyet etkili olabilmesi için alış maliyetinin düşürülmesi önerilmektedir.

Makale detayları

COST-EFFECTIVENESS OF LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW

Yazarlar:

Mustafa Zeybek | Vahit Yiğit

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Sağlık Yönetimi

Dergi:

SDÜ Sağlık Yönetimi Dergisi Vol.6 Issue 1, pp.13-27

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001320991

pISSN:

2757-5888

Heart Failure

Heart Transplantation

LVAD

Economic Evaluation

Systematic ReviewKalp Yetmezliği

Kalp Nakli

LVAD

Ekonomik Değerlendirme

Sistematik Tarama

Sayı

Makale detayları

Yazarlar: Mustafa Zeybek | Vahit Yiğit

Yayıncı: Süleyman Demirel University

Ana Başlıklar: Sağlık Yönetimi

Dergi: SDÜ Sağlık Yönetimi Dergisi Vol.6 Issue 1, pp.13-27

Belge Tipi: Makale

Yayın Tarihi: 6/2024

Belge Dili: Türkçe

Document ID (Org No.): 2001320991

pISSN: 2757-5888

Sayı

Yazarlar:

Mustafa Zeybek | Vahit Yiğit

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Sağlık Yönetimi

Dergi:

SDÜ Sağlık Yönetimi Dergisi Vol.6 Issue 1, pp.13-27

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001320991

pISSN:

2757-5888